Budesonide – Oral Galenic Formulations for Crohn Disease
Article Sidebar
Main Article Content
Abstract
The aim of this work is to verify the pharmaceutical form in the galenic field of oral Budesonide compounded used in Crohn’s disease: capsules delay release or oral suspension. In particular ways the kinds of excipients or bases-vehicle used in the galenic pharmacy practice. The therapeutic need for Crohn’s disease requires a release of the API in delayed-release DR. The Budesonide molecule shows low systemic impacts due to its hepatic metabolism vs. a topical effect useful in this pathology. In this work, the oral pharmaceutical forms are analyzed: modified-release capsules and oral suspension with specific advantages for each one. Some formulations provided by various pharmacies are reported in this work as well as new technology like the 3D-PRINTING systems for colonic targeting tablets.
Article Details
Copyright (c) 2024 Luisetto M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Kelsen J, Baldassano R N. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis. 2008;14(suppl_2):S9-11. Available from: https://doi.org/10.1002/ibd.20560
Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088-1103. Available from: https://doi.org/10.1016/j.mayocp.2017.04.010
Brandi Jones M-E, Rekhi S. What’s the difference between Crohn’s disease and ulcerative colitis? Health. 2024 Feb 7. Available from: https://www.health.com/crohns-disease-vs-ulcerative-colitis-8405457
Crohn’s Disease. Johns Hopkins Medicine. 2022 Apr 19. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/crohns-disease
von Allmen D. Pediatric Crohn's disease. Pediatr Congenit Colorectal Dis Adult Patient. 2018;31(2):80-88. Available from: https://doi.org/10.1055/s-0037-1609022
Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Ther Adv Gastroenterol. 2022;15:17562848221078456. Available from: https://doi.org/10.1177/17562848221078456
Greenberg G R, Feagan B G, Martin F, Sutherland L R, Thomson A, Williams C N, et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994;331(13):836-841. Available from: https://doi.org/10.1056/nejm199409293311303
Budesonide 2 mg/10 ml Oral Suspension | Formulas | Bayview Pharmacy. Available from: https://www.bayviewrx.com/formulas/Budesonide-2-mg-10-ml-Oral-Suspension-Asthma-Allergic-Rhinitis-Crohn-s-Disease-Ulcerative-Colitis-Eosinophilic-Esophagitis
Budesonide (oral route). Mayo Clinic. 2024 Oct 1. Available from: https://www.mayoclinic.org/drugs-supplements/budesonide-oral-route/description/drg-20073233
Budesonide Te Arai. Budesonide Te Arai Data Sheet v 3.0 July 2023. Available from: https://www.medsafe.govt.nz/profs/datasheet/b/BudesonideTeAraicap.pdf
Hennig M, Hennig M. Colon-targeted delivery systems of budesonide as second-line therapy in inflammatory bowel disease. Pharma Excipients. 2024 Feb 25. Available from: https://www.pharmaexcipients.com/news/budesonide-second-line/
O'Donnell S, O'Morain CA. Therapeutic benefits of budesonide in gastroenterology. Ther Adv Chronic Dis. 2010;1(4):177-186. Available from: https://doi.org/10.1177/2040622310379293
Budesonide 10 mg Slow Release Acid Resistant Capsules | Formulas | Bayview Pharmacy. Available from: https://www.bayviewrx.com/formulas/Budesonide-10-mg-Slow-Release-Acid-Resistant-Capsules-Asthma-Crohn-s-Disease-Ulcerative-Colitis-Allergic-Rhinitis-Eosinophilic-Esophagitis
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. 5th ed. Pharmaceutical Press; 2006;918. https://books.google.co.in/books/about/Handbook_of_Pharmaceutical_Excipients.html?id=BGJqAAAAMAAJ
Yokoyama T, Ohta A, Motoya S, Takazoe M, Yajima T, Date M, et al. Efficacy and safety of oral budesonide in patients with active Crohn's disease in Japan: a multicenter, double-blind, randomized, parallel-group phase 3 study. Inflamm Intest Dis. 2018;2(3):154-162. Available from: https://doi.org/10.1159/000484047
Chopra A, Pardi DS, Loftus EV, Tremaine WJ, Egan LJ, Faubion WA, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bowel Dis. 2006;12(1):29-32. Available from: https://doi.org/10.1097/01.mib.0000192323.82426.83
Ou YH, Goh WJ, Lim SH. Form & formulation approaches for COntRollable Release in 3D printed Colonic Targeting (CORR3CT) budesonide tablet. Int J Pharm. 2023;635:122680. Available from: https://doi.org/10.1016/j.ijpharm.2023.122680
Cortesi R, Ravani L, Menegatti E, Esposito E, Ronconi F. Eudragit® microparticles for the release of budesonide: a comparative study. Indian J Pharm Sci. 2012;74(5):415-421. Available from: https://doi.org/10.4103/0250-474x.108416
Iborra M, Álvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol. 2014;39-46. Available from: https://doi.org/10.2147/ceg.s34715
Dressman J. Comparative dissolution of Budesonide from four commercially available products for oral administration: implications for interchangeability. Dissol Technol. 2023;30:224-229. Available from: https://dissolutiontech.com/issues/202311/DT202311_A02.pdf
Management. MMXTM technology and its applications in gastrointestinal diseases - Tasnim Pharmaceutical Company. Tasnim Pharmaceutical Company. 2023 Jul 19. Available from: https://tasnimpharma.com/mmx-technology/
Moghrabi FS, Fadda HM. Drug physicochemical properties and capsule fill determine extent of premature gastric release from enteric capsules. Pharmaceutics. 2022;14(11):2505. Available from: https://doi.org/10.3390/pharmaceutics14112505
Shin-Etsu technical information - SE Tylose. Extended Release of Vitamin C Matrix Tablets with TYLOPUR Xtend Nutra®. Available from: https://www.setylose.com/en/knowledge-base/healthcare/technical-information#tylopur-xtend-nutra-10231